New drugs are on the rise! Small cell lung cancer expected to take off the "Magic King" hat
-
Last Update: 2020-06-15
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
When small cell lung cancer is detected, metastasis is often occurred, the prognosis is poor, the five-year survival rate is less than 10%But in recent years, with the breakthrough of immunotherapy, many patients with small cell lung cancer ushered in new treatment hopesPD-L1 inhibitor atlizumab (commodity name: Tesan Chi Tecentriq) has been approved for use with platinum-containing chemotherapy, the first line of treatment for patients with a wide range of small cell lung cancerIn March 2020, the U.SFDA approved the treatment of adult patients with small cell lung cancer with chemotherapy of the U.SMonosau-Popoplusa platinum or cisplatin standard (SoC)Currently, the drug has not been approved in any market outside the United States for the treatment of small cell lung cancer.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
![benzyl N-{2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl}carbamate](https://file.echemi.com/fileManage/upload/goodpicture/20210823/m20210823171124543.jpg)
